Circulating autoantibody biomarkers to supplement lung cancer screening protocols
OwnerJeffrey Allen Borgia, Claire Augerinventors
Life of this patent
Estimating the term…
Abstract
Methods and autoantibody biomarker panels are disclosed that are suitable for detecting and differentiating an actionable lung nodule from a non-actionable lung nodule in a subject using a biological sample obtained from the subject.
Claims74
A method of detecting an actionable lung nodule in a subject comprising:
- contacting a biological sample obtained from the subject comprising an autoantibody biomarker with a target protein,
- detecting the binding of the target protein with the autoantibody biomarker which is specific to the target protein;
- measuring a level of the autoantibody biomarker present in the biological sample;
- wherein the level is indicative of an actionable lung nodule when compared to a reference sample.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(Canceled)
(canceled)
The method of claim 48, wherein the target proteins are selected from the group consisting of ANNEXIN 2, KEAP1, HNRNPD, IMPDH2, NAP1L5, UBIQUILLIN 1, UBIQUILLIN 2, ANNEXIN 1, NIP30, CFAP36, MID1P1, DCD, TAF10, MED21, ZNF696, DR1, HSP70, GPBP1, MYBPH, PGAM1, IKZF5, NAT9, RAB27A, SGPL1, and TP53. (Currently Amended) The method of claim 1, wherein detection of the autoantibody biomarker is performed using a detection method selected from mass spectrometry, immunoassay, electrochemical luminescent assay, electrochemical voltametry, electrochemical amperometry, atomic force microscopy, radio frequency multipolar resonance spectroscopy, confocal microscopy, non-confocal microscopy, fluorescence optical detection, luminescence optical detection, chemiluminescence optical detection, absorbance optical detection, reflectance optical detection, transmittance optical detection, birefringence optical detection, refractive index detection, surface plasmon resonance, ellipsometry, resonant mirror detection, grating coupler waveguide detection, interferometry, or a combination thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An autoantibody biomarker panel comprising N target proteins, wherein N=1 to 26, and wherein each target protein is specific to an autoantibody for the detection of an actionable lung nodule.
(canceled)
(canceled)
(canceled)
(canceled)
A method of diagnosing an actionable lung nodule in a subject comprising:
- contacting a biological sample obtained from the subject comprising an autoantibody biomarker with a target protein, which is specific to the autoantibody, to form a bound autoantibody;
- contacting the bound antibody with a detection molecule;
- determining a level of the bound autoantibody present in the biological sample;
- providing a diagnosis based on the level of the bound autoantibody biomarker compared to a reference sample, wherein an altered level is indicative of an actionable lung nodule.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.